Medxy AI – Page 81

Mediterranean Diet Outperforms Other Dietary Patterns in Reducing Mortality via Inflammatory Pathways: Insights from a Causal Inference Analysis

By MedXY 09/17/2025

A causal analysis of nine dietary patterns reveals the Mediterranean diet as most effective in reducing all-cause and cardiovascular mortality, primarily through modulation of inflammatory biomarkers such as CRP, NPR, and SII.

Clinical Updates General Surgery Specialties

Reducing Delayed Hyponatremia After Endoscopic Transsphenoidal Surgery: The Role of Postoperative Fluid Restriction

By MedXY 09/17/2025

A prospective randomized study demonstrates that postoperative fluid restriction significantly reduces delayed hyponatremia and hospital readmission following endoscopic endonasal transsphenoidal surgery for pituitary tumors.

Cardiology Diabetes & Endocrinology news Specialties

Tirzepatide’s Efficacy in HFpEF and Obesity: Unraveling Diabetes’ Influence from the SUMMIT Trial

By MedXY 09/17/2025

The SUMMIT trial reveals that tirzepatide improves heart failure outcomes and quality of life in obese HFpEF patients with or without type 2 diabetes, despite attenuated weight loss in diabetic patients.

Clinical Updates Diabetes & Endocrinology news Ophthalmology Specialties

Oral Lamivudine: A Promising Alternative in the Management of Diabetic Macular Edema

By MedXY 09/17/2025

A recent randomized, double-blind trial demonstrates that oral lamivudine significantly improves visual acuity in patients with center-involved diabetic macular edema, offering a cost-effective and safer alternative to conventional anti-VEGF therapy.

Cardiology news Specialties

Paclitaxel-coated vs Uncoated Devices in Infrainguinal Revascularisation: Insights from the SWEDEPAD 2 Trial

By MedXY 09/17/2025

The SWEDEPAD 2 trial reveals that paclitaxel-coated devices do not improve quality of life at 1 year and raise concerns about increased 5-year mortality in patients with intermittent claudication undergoing lower limb revascularisation.

Cardiology news Specialties

Paclitaxel-Coated vs Uncoated Devices in Chronic Limb-Threatening Ischaemia: Insights from the SWEDEPAD 1 Trial

By MedXY 09/17/2025

The SWEDEPAD 1 trial evaluated paclitaxel-coated versus uncoated devices for infrainguinal revascularisation in chronic limb-threatening ischaemia, finding no significant reduction in major amputations or mortality over a median 2.7-year follow-up.

Clinical Updates Diabetes & Endocrinology news Specialties

Orforglipron: A Promising Oral Small-Molecule GLP-1 Receptor Agonist for Early Type 2 Diabetes and Obesity Management

By MedXY 09/17/2025

Orforglipron demonstrates significant glycemic control and weight reduction benefits in early type 2 diabetes and obesity, with favorable safety and oral administration convenience.

Diabetes & Endocrinology news Specialties

Oral Semaglutide 25 mg: A New Oral Therapeutic Option for Weight Management in Overweight and Obese Adults

By MedXY 09/17/2025

Oral semaglutide 25 mg once daily significantly reduces body weight versus placebo and improves physical function in adults with overweight or obesity, offering an alternative to injectable formulations.

Clinical Updates news

Dapagliflozin’s Effects on Hormonal Regulation and Ketone Production in Adults with Type 1 Diabetes: Insights from a Randomised Controlled Crossover Trial

By MedXY 09/17/2025

This trial evaluates dapagliflozin's impact on key hormones and ketogenesis in type 1 diabetes, demonstrating increased ketone bodies without altering GLP-1, glucagon, or somatostatin secretion, highlighting risks and benefits for adjunct therapy.

Clinical Updates Diabetes & Endocrinology news Specialties

Early Insulin Sensitization by Tirzepatide in Japanese Patients with Obesity and Type 2 Diabetes: Insights from a Hyperinsulinaemic-Euglycaemic Clamp Study

By MedXY 09/17/2025

A 12-week prospective study demonstrates tirzepatide significantly improves insulin sensitivity in obese Japanese patients with type 2 diabetes, independent of weight loss, as assessed by hyperinsulinaemic-euglycaemic clamp.

Clinical Updates news

Ervogastat Alone and Combined with Clesacostat for Metabolic Dysfunction-Associated Steatohepatitis with Advanced Fibrosis: Insights from the MIRNA Phase 2 Trial

By MedXY 09/17/2025

The MIRNA study evaluated ervogastat, alone and with clesacostat, in patients with biopsy-confirmed MASH and F2-F3 fibrosis, showing combination therapy achieved significant efficacy in resolving MASH without fibrosis worsening and a manageable safety profile.

Clinical Updates Diabetes & Endocrinology Specialties

Efficacy and Safety of cAMP-Biased GLP-1 Receptor Agonist Ecnoglutide Versus Dulaglutide in Type 2 Diabetes: Insights from the EECOH-2 Phase 3 Trial and Broader Clinical Context

By MedXY 09/17/2025

Ecnoglutide, a novel cAMP-biased GLP-1 receptor agonist, demonstrated non-inferior glycemic control and comparable safety to dulaglutide at 52 weeks in type 2 diabetes patients on metformin, offering a promising new treatment option.

$Pitolisant as Adjunct Therapy for Refractory Restless Legs Syndrome: Insights from a Pilot Study$

Clinical Updates Neurology news Pediatrics Specialties

Pitolisant as Adjunct Therapy for Refractory Restless Legs Syndrome: Insights from a Pilot Study

By MedXY 09/17/2025

This pilot study reveals that adjunctive pitolisant, a histamine-3 inverse agonist, is well tolerated and improves symptom scales in refractory restless legs syndrome, suggesting potential to address daytime consequences with minimal core symptom relief. Controlled trials are warranted.

$Camlipixant for Refractory Chronic Cough: Promising Phase 2b Trial Results and Clinical Implications$

Clinical Updates news Respiratory Specialties

Camlipixant for Refractory Chronic Cough: Promising Phase 2b Trial Results and Clinical Implications

By MedXY 09/17/2025

The SOOTHE phase 2b trial demonstrates that camlipixant, a P2X3 antagonist, significantly reduces cough frequency and improves quality of life in refractory chronic cough patients, with a favorable safety profile, supporting its potential as a new therapeutic option.

Clinical Updates Respiratory Specialties

Bexotegrast Shows Promise in Treating Idiopathic Pulmonary Fibrosis: Insights from the INTEGRIS-IPF Phase 2a Trial

By MedXY 09/17/2025

The INTEGRIS-IPF trial demonstrates that bexotegrast is well tolerated and may reduce lung function decline in IPF patients, offering hope for a novel antifibrotic therapy.

Clinical Updates Infectious Diseases Respiratory Specialties

Optimizing Pyrazinamide Dosing in Drug-Susceptible Pulmonary Tuberculosis: Insights from a Large Phase 3 Trial

By MedXY 09/17/2025

A comprehensive analysis from the TBTC Study 31/ACTG A5349 reveals that flat dosing of pyrazinamide at 1,000 mg daily optimizes efficacy and safety, challenging current weight-banded dosing strategies for drug-susceptible tuberculosis.

Critical Care Neurology Specialties

Lung-Protective Mechanical Ventilation in Acute Brain Injury: Insights from the PROLABI Trial

By MedXY 09/17/2025

The PROLABI trial assessed lung-protective ventilation in acute brain injury patients and found no improvement in mortality, ventilator dependency, or ARDS incidence, highlighting the need for further research in this population.

Clinical Updates Diabetes & Endocrinology Family Medicine & Nutrition news Specialties

Optimizing Metabolic and Physical Health in Obese Older Adults: Impact of Exercise Modalities on Insulin Secretion, CNTF, and IGF-1 During Weight Loss

By MedXY 09/17/2025

Combining aerobic and resistance exercise with diet-induced weight loss in obese older adults significantly improves insulin secretion, preserves CNTFRα levels, and increases IGF-1, enhancing metabolic and physical function.

Diabetes & Endocrinology Family Medicine & Nutrition news Specialties

Hydroxytyrosol Supplementation Enhances Antioxidant and Anti-Inflammatory Status in Overweight Prediabetic Adults: Insights from a Randomized Controlled Trial

By MedXY 09/17/2025

A 16-week randomized trial demonstrates that daily hydroxytyrosol supplementation significantly reduces oxidative stress and inflammatory markers in overweight individuals with prediabetes, highlighting its potential in preventing aging-related diseases.

Neurology news Specialties

Electrical Vestibular Stimulation: A Promising Adjunct Therapy for Adult Insomnia in Hong Kong

By MedXY 09/17/2025

A double-blind, randomized trial demonstrates that electrical vestibular stimulation (VeNS) significantly reduces insomnia severity and improves quality of life in adults, highlighting a novel non-pharmacological treatment option.

Mediterranean Diet Outperforms Other Dietary Patterns in Reducing Mortality via Inflammatory Pathways: Insights from a Causal Inference Analysis

Reducing Delayed Hyponatremia After Endoscopic Transsphenoidal Surgery: The Role of Postoperative Fluid Restriction

Tirzepatide’s Efficacy in HFpEF and Obesity: Unraveling Diabetes’ Influence from the SUMMIT Trial

Oral Lamivudine: A Promising Alternative in the Management of Diabetic Macular Edema

Paclitaxel-coated vs Uncoated Devices in Infrainguinal Revascularisation: Insights from the SWEDEPAD 2 Trial

Paclitaxel-Coated vs Uncoated Devices in Chronic Limb-Threatening Ischaemia: Insights from the SWEDEPAD 1 Trial

Orforglipron: A Promising Oral Small-Molecule GLP-1 Receptor Agonist for Early Type 2 Diabetes and Obesity Management

Oral Semaglutide 25 mg: A New Oral Therapeutic Option for Weight Management in Overweight and Obese Adults

Dapagliflozin’s Effects on Hormonal Regulation and Ketone Production in Adults with Type 1 Diabetes: Insights from a Randomised Controlled Crossover Trial

Early Insulin Sensitization by Tirzepatide in Japanese Patients with Obesity and Type 2 Diabetes: Insights from a Hyperinsulinaemic-Euglycaemic Clamp Study

Ervogastat Alone and Combined with Clesacostat for Metabolic Dysfunction-Associated Steatohepatitis with Advanced Fibrosis: Insights from the MIRNA Phase 2 Trial

Efficacy and Safety of cAMP-Biased GLP-1 Receptor Agonist Ecnoglutide Versus Dulaglutide in Type 2 Diabetes: Insights from the EECOH-2 Phase 3 Trial and Broader Clinical Context

Pitolisant as Adjunct Therapy for Refractory Restless Legs Syndrome: Insights from a Pilot Study

Camlipixant for Refractory Chronic Cough: Promising Phase 2b Trial Results and Clinical Implications

Bexotegrast Shows Promise in Treating Idiopathic Pulmonary Fibrosis: Insights from the INTEGRIS-IPF Phase 2a Trial

Optimizing Pyrazinamide Dosing in Drug-Susceptible Pulmonary Tuberculosis: Insights from a Large Phase 3 Trial

Lung-Protective Mechanical Ventilation in Acute Brain Injury: Insights from the PROLABI Trial

Optimizing Metabolic and Physical Health in Obese Older Adults: Impact of Exercise Modalities on Insulin Secretion, CNTF, and IGF-1 During Weight Loss

Hydroxytyrosol Supplementation Enhances Antioxidant and Anti-Inflammatory Status in Overweight Prediabetic Adults: Insights from a Randomized Controlled Trial

Electrical Vestibular Stimulation: A Promising Adjunct Therapy for Adult Insomnia in Hong Kong

High-Dose Oral Rifampin Did Not Improve Survival in Tuberculous Meningitis—HARVEST Trial Shows No Benefit and Possible Harm

Validated PRESEV Score Identifies Adults with Sickle Cell VOC at Low Risk for Acute Chest Syndrome — Implications for Safer Outpatient Management

Probiotics Cut Clostridioides difficile Risk in Antibiotic-Exposed Patients — Small Benefit, Low Certainty

High-frequency Oscillatory Ventilation in Near‑Term and Term Infants: Inconclusive Benefit and Possible Increased Mortality — What the 2025 Cochrane Update Tells Clinicians